274 related articles for article (PubMed ID: 19506475)
1. Dopamine agonists and valvular heart disease.
Cheung D; Heaney A
Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
[TBL] [Abstract][Full Text] [Related]
2. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
3. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Vallette S; Serri K; Serri O
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
[TBL] [Abstract][Full Text] [Related]
5. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
6. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
Valassi E; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
[TBL] [Abstract][Full Text] [Related]
7. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
Kars M; Pereira AM; Bax JJ; Romijn JA
Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568
[TBL] [Abstract][Full Text] [Related]
8. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
9. Cabergoline use for pituitary tumors and valvular disorders.
Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Yamamoto M; Uesugi T; Nakayama T
Neurology; 2006 Oct; 67(7):1225-9. PubMed ID: 17030757
[TBL] [Abstract][Full Text] [Related]
11. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.
Delgado V; Biermasz NR; van Thiel SW; Ewe SH; Marsan NA; Holman ER; Feelders RA; Smit JW; Bax JJ; Pereira AM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):99-105. PubMed ID: 22211510
[TBL] [Abstract][Full Text] [Related]
12. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
14. Prolactin excess: treatment and toxicity.
Gillam MP; Fideleff H; Boquete HR; Molitch ME
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
[TBL] [Abstract][Full Text] [Related]
15. Bromocriptine use and the risk of valvular heart disease.
Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
[TBL] [Abstract][Full Text] [Related]
16. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
17. Update in prolactinomas.
Kars M; Dekkers OM; Pereira AM; Romijn JA
Neth J Med; 2010 Mar; 68(3):104-12. PubMed ID: 20308704
[TBL] [Abstract][Full Text] [Related]
18. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
Roth J; Ulmanová O; Růzicka E
Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
[TBL] [Abstract][Full Text] [Related]
19. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
20. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]